Tag - IMV

Markets

Leede Jones Gable starts IMV at speculative buy; PT $10.50 (Canadian)

Leede Jones Gable launched coverage of IMV (TSX:IMV) with a “speculative buy” and price target of $10.50 (Canadian). The stock closed at $4.03 on Dec. 15. IMV’s flagship technology platform is the lipid-based water-free...

December 16, 2020

Markets

BTIG cuts IMV PT to $5 from $8

BTIG lowered its price target for IMV (NASDAQ, TSX:IMV) to $5 from $8, citing uncertainty about data from the company’s ongoing Phase 2 study of DPX-Survivac in patients with advanced recurrent ovarian cancer. The stock...

February 28, 2020

Developments

Echelon adds top pick status to Immunovaccine

Echelon Wealth Partners ascribed 2017 top pick status to Immunovaccine (TSX:IMV; OTCQX:IMMVF) while maintaining a “speculative buy” rating and $2.75 price target. The stock closed at $1.24 on Oct. 11. Analyst Doug Loe...

October 12, 2017

Feature

Immunovaccine targets three clinical milestones

By Len Zehr Immunovaccine (OTCQX:IMMVF; TSX:IMV) expects to report three clinical milestones for its killer T cell activation vaccine platform, DepoVax, in ovarian and HPV cancers in the next 12 months. “Our DepoVax...

October 18, 2016

Tag - IMV

Leede Jones Gable starts IMV at speculative buy; PT $10.50 (Canadian)

BTIG cuts IMV PT to $5 from $8

Echelon adds top pick status to Immunovaccine

Immunovaccine targets three clinical milestones

General

More